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Abstract:  
Adherence to adjuvant endocrine therapy (AET) following breast cancer is known to be sub-
optimal despite its known efficacy in reducing recurrence and mortality.  This study aims to 
investigate factors associated with non-adherence and inform the development of 
interventions to support women and promote adherence. A questionnaire survey to measure 
level of adherence, side effects experienced, beliefs about medicine, support received and 
socio-demographic details was sent to 292 women 2-4 years post breast cancer diagnosis.  
Differences between non-adherers and adherers to AET were explored, and factors associated 
with intentional and unintentional non-adherence are reported. Approximately one quarter of 
respondents, 46 (22%), were non-adherers, comprising 29 (14%) intentional non-adherers 
and 17 (8%) unintentional non-adherers.  Factors significantly associated with intentional 
non-adherence were: the presence of side effects (p<0.03), greater concerns about AET 
(p<0.001), and a lower perceived necessity to take AET (p<0.001).  Half of the sample 
(105/211) reported that side effects had a moderate or high impact on their quality of life.   
Factors associated with unintentional non-adherence were: younger age (<65), (p<0.001), 
post-secondary education (p=0.046), and paid employment (p=0.031).  There are distinct 
differences between intentional non-adherence and unintentional non-adherence.  
Differentiation between the two types of non-adherence may help tailor support and advice 
interventions 
 
 
Key words: Adjuvant endocrine therapy, breast cancer, non-adherence, intentional non-
adherence, BMQ, side effects 
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Background: 
 
In the UK, approximately two thirds of breast cancers diagnosed are oestrogen receptor 
positive (ER +ve) and for these women use of adjuvant endocrine therapy (AET), such as 
tamoxifen or an aromatase inhibitor, reduces the risk of breast cancer recurrence and 
mortality(Davies et al.2013; Hind et al. 2007).  To gain the potential benefits of AET, women 
need to adhere to the medication as prescribed, yet studies report sub-optimal adherence, with 
almost half of all women not completing the currently recommended 5-year course of 
treatment (Makubate et al. 2013; McCowan et al. 2008).  A systematic review of studies in 
clinical practice found persistence over 5 years as between 31% and 73% (Murphy et al. 
2012). Other reviews report that up to 50% of women either do not take the correct dosage at 
the prescribed frequency or discontinue therapy (Banning 2012; Gotay & Dunn 2011; Hadji 
2010; Chlebowski & Geller 2006).   Low adherence to adjuvant endocrine therapy is 
associated with reduced quality-adjusted life years (QALYs), increased medical costs and a 
30% increased risk of mortality due to recurrence (Makubate et al. 2013; Murphy et al. 2012 
McCowan et al. 2008). It has been calculated that, in the UK setting, encouraging women to 
take their full course of AET could save 400 to 500 lives every year and bring substantial 
benefit to health service budgets by potentially freeing up nearly £30 million per year 
(Makubate et al. 2013; Hershman et al, 2011).  High adherence to AET would also benefit 
both patients and health care services internationally (Yang et al, 2010; Delea et al, 2006; 
Glaziou 1994). 
 
Factors previously associated with low adherence to medication include side effects, anxiety 
and depression, poor patient- clinician relationships, forgetfulness, medication concerns, 
limited belief in the efficacy of the medication, and demographic factors (Wickersham et al, 
2012; Wouter et al, 2013; Khan et al, 2009; Fink et al, 2004).    Horne & Wienman (1999) 
developed a useful conceptual model for understanding patients’ perspectives and beliefs on 
prescribed medicines (Horne & Weinman 1999). He also distinguished between two broad 
categories of non-adherers: intentional and unintentional non-adherers.  Unintentional non-
adherence occurs when a patient finds it difficult to schedule, administer or remember the 
treatment, or lack capacity to self-manage the medication themselves Horne et al, 2013).  
Intentional non-adherence occurs when a patient consciously decides not to follow the 
recommendations. This is best understood in terms of perceptual factors (e.g. beliefs around 
the medication and preferences to avoid side effects) influencing motivation to start and 
continue with treatment (Clifford et al, 2008; Aikens et al, 2005).   How patients’ beliefs 
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about medication affect intentional and unintentional adherence has been explored in other 
disease groups (Molloy 2014; Horne et al, 2013; Clifford et al, 2008). 
 
While previous evidence has reported on factors affecting non-adherence to AET, such as 
side effects, concerns around toxicity, and psycho-social factors (Cahir 2015, Van Liew 2014, 
Hadji 2013, Harrow 2013), none have identified the extent to which behaviour is 
intentionally non-adherent or unintentionally non-adherent.  However, characterisation by the 
different behaviours is important to inform the development of interventions to improve 
adherence.   This study therefore aims to identify factors associated with non-adherence (both 
intentional and unintentional) to AET to inform interventions to support women, promote 
adherence and ultimately improve outcomes for women with breast cancer.    
 
Methods 
Design 
The study is a cross sectional survey of a sub-group of participants in an existing cohort study 
 
Recruitment  
Women from the Joint Aches Cohort study (JACS) (Fenlon et al, 2014) were invited to 
participate. The JACS study was set up in 2010 to explore the onset of joint pain following 
breast cancer treatment. All patients diagnosed with primary breast cancer within a set time 
frame were invited at surgery and prior to adjuvant treatment, to participate in a questionnaire 
study. 543 women took part, representing 57% of the eligible cohort. Of these women 292 
had been prescribed AET and were invited to participate in the current study, by a letter from 
the original study research team (Fenlon et al, 2014). All had previously indicated consent to 
participate in future research. 
 
Those who wished to take part were asked to complete and return a postal questionnaire 
which addressed their experiences and beliefs about AET.  Postal questionnaires were sent 
out in July 2014, with a single reminder sent to non-responders after 3 weeks.  Ethics 
approval was gained through Oxford Brookes University, supplementing NRES approval for 
the original cohort study. 
 
Questionnaire 
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The questionnaire comprised the following validated measures and additional questions to 
address areas of interest where no existing measures were available.  The final questionnaire 
took approximately 20 minutes to complete. 
 
The Beliefs about Medicine Questionnaire (BMQ) (Horne & Weinman 1999) assesses 
individuals’ specific beliefs and understanding of the medication they are taking as well as 
general attitudes to taking medicines (Horne & Weinman 1999).  The measure comprises two 
sections, each divided into two subscales.  The BMQ-Specific comprises two five item 
subscales: the ‘Specific Necessity’ subscale (i.e. beliefs about the necessity of taking that 
specific medication to remain healthy) and the ‘Specific Concerns’ subscale (i.e. concerns 
about the negative effects of taking that specific medication). The BMQ-General comprises 
two 4-item subscales: the ‘General Harm’ subscale which assesses beliefs about medicines as 
harmful, addictive, poisons which should not be taken continuously and the ‘General 
Overuse’ subscale which assesses beliefs that medicines are overused by doctors. For this 
study the wording of the items in the BMQ-Specific section were modified, as advised by 
Horne et al (1999), to be more specific to women taking AET after breast cancer and to 
ensure face validity.  
 
All items of the BMQ are rated on a 5-point likert scale where 1 represents strongly agree, 
and 5 represents strongly disagree. Scores obtained for the individual items are summed to 
give a total score for each subscale.  A lower score equals a stronger belief. For example, a 
lower score on the Specific Necessity scale is a stronger belief in the necessity of taking the 
medication; a lower score on the Specific Concerns scale implies stronger belief of concerns 
about taking the medication (Horne et al, 2013; Horne et al, 2006).  Total scores for the 
Necessity and Concerns subscales range from 5 to 25 and total scores for the Harm and 
Overuse subscales range from 4 to 20.  The two sections of the BMQ can be used in 
combination or separately, but are reported separately in this paper. Psychometric evaluation 
of the BMQ in this population has been tested (Brett J et al, 2016). 
 
The Medical Adherence Report Scale (MARS-5) (Thompson 2000)  assesses adherence to 
treatment. The MARS-5 consists of five general statements about suboptimal adherence 
behaviour (I forget to take my AET medicine, I alter the dose of my AET medicine, I stop 
taking my AET medicine for a while, I decide to skip one of my AET tablets, I take AET less 
than prescribed) answered on a 5 point scale where 1 represents ‘always’, and 5 represents 
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‘never’. We included an additional item ‘I don’t order my prescription on time’ as this was 
raised as an issue by patient representatives in a pre-test of the questionnaire. Items were not 
summed but used individually in determining types of adherence and non-adherence. 
Four additional questions to assess levels of adherence were also
 
included: 1) Are you still 
taking AET? (Yes, no stopped completely, no stopped temporarily); 2) Have you ever taken a 
break from AET? (Yes I have taken a break [length of time], Yes I have considered stopping 
but have not actually done so, No I have never taken a break or considered stopping), 3) In 
the last week have you taken AET every day? (Yes, no, not sure, not applicable), and 4) How 
frequently do you take AET? (Daily, Most days, At least three times a week, less than once a 
month).  
 
MARS and the additional questions were combined to overcome issues of under-reporting of 
non-adherence (Molloy et al, 2014; Hamilton 2003; Sewitch et al, 2003). Items 1 and 6 of the 
MARS refer to unintentional non-adherence, and items 2-5 refer to intentional non-adherence 
(Molloy 2015). Single item questions about adherence have been shown to correlate with the 
MARS in identifying the nature of adherence (Hamilton 2003).   
 
Using the MARS and the four independent questions about level of adherence, the sample 
was divided into three groups. Two non-adherer groups (unintentional non-adherers and 
intentional non-adherers) and adherers:  
 
 Adherers (Still taking AET, never had a break from AET, never considered stopping 
taking AET, taking AET daily in the last week, score >=4 on all MARS items); 
 
 Intentional non-adherence (have stopped taking AET permanently, have stopped 
taking AET  temporarily, have taken a break from AET, score ≤3 on MARS 
statements ‘I change my dose of my hormone treatment’, I stop taking my hormone 
treatment for a while’, ‘I decide to skip one of my treatments’, ‘I take the treatment 
less than prescribed’  
 
 Unintentional non-adherence (Intending to adhere:  Still taking AET, never had a 
break from AET, never considered stopping taking AET.  But not taking as 
prescribed:  not taken daily, score ≤3 on MARS statements ‘I forget to take my AET, 
and I don’t order my prescription on time); 
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Additional questions were included on side effects experienced and their impact on daily life, 
and whether AET was discussed at hospital follow-up appointments or with the General 
Practitioner (GP) in primary care.  Demographic data were collected, including age, marital 
status, employment status, education, and ethnic group. 
 
Statistical Analysis:  
Data were analysed using SPSS version 21.   Descriptive statistics were performed for the 
sample as a whole.  T-tests were conducted to explore differences between adherers and non-
adherers for the BMQ.  Factors significantly associated with intentional and unintentional 
non-adherence were explored using Pearson chi-square test of independence, with p<0.05 as 
the chosen level of significance, and using adherers as the comparison group.  A final logistic 
regression was performed to identify predictors of non-adherence, comparing all non-
adherers vs all adherers. 
 
Results 
Two hundred and eleven completed questionnaires were returned, a response rate of 73%.  
The majority of women (165, 78%) were adherers to AET, although 20 (9%) had 
contemplated stopping.  Approximately one quarter of respondents, 46 (22%), were non-
adherers, comprising 29 (14%) intentional non-adherers and 17 (8%) unintentional non-
adherers.   
 
Demographic and clinical characteristics of the sample are summarised in Table 1.   
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Side effects of AET and the impact on adherence 
A total of 127 (60%) women reported side effects, with a significantly higher proportion of 
non-adherers (41/49, 84%) than adherers 86/165 (52%) reporting them (p<0.001).  The most 
common side effects reported were hot flushes, joint ache or pain, weight gain, fatigue and 
tiredness and depression/low mood.  Other side effects reported were vaginal dryness and 
vaginal discharge, lack of concentration, low esteem and low confidence, and low libido.  Of 
those who reported a side effect, 83% (105/127) stated this had a moderate to high impact on 
their lives.  Table 2 reports the total number reporting side effects, the proportion reporting 
the most common side effects, and the proportion reporting that these side effects had a 
moderate to high impact on their lives 
 
A significant association between ‘having side effects’ and ‘intentional non-adherence’ was 
reported (χ2=0.178, 1 df, p<0.03).  The relationship was stronger between ‘having side 
effects with moderate to high impact on life’ and ‘intentional non-adherence’  (χ2=0.290, 1 
df, p<0.01).   No significant association between having side effects and unintentional 
nonadherence (χ2=0.038 (1 df), p=0.962) was found. 
 
Beliefs about medicine and impact on adherence 
Table 3 presents the mean scores for adherers and non-adherers of AET for each of the BMQ 
Specific Beliefs and Specific Necessity and Concerns subscale items and for the summary 
scores.   Non-adherers had significantly greater concerns and significantly lower belief in the 
necessity of taking AET for the summary scores and for all individual items, except for one 
item, ‘Hormone treatment is a mystery to me’, where both adherers and non-adherers were 
similarly ‘uncertain’. 
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A significant association was found between intentional non-adherence and both greater 
concerns about AET  (BMQ Concerns) (χ2=0.542 (1df), p<0.001), and lower belief in the 
necessity to take AET (BMQ Necessity (χ2= 0.443 (1df), p<0.001). No significant 
associations were found between unintentional non-adherence and concerns about the 
medication or belief in the necessity to take AET. 
 
 
 
General Beliefs of taking medication and impact on adherence 
Table 4 presents the mean scores for adherers and non-adherers for each of the BMQ General 
Harm and BMQ General Overuse subscale items and for the summary scores.   
 
No significant differences between adherers and non-adherers were found for mean BMQ 
harms scores or mean BMQ overuse scores either for the individual items or the summary 
scores.  No significant association was found between intentional and unintentional non-
adherence and the BMQ General Harms or BMQ General Overuse items or summary scores. 
 
Support from health professionals and impact on adherence: 
Of those still attending hospital clinic appointments, 51% (92/179) reported AET was always 
discussed, 34% (60/179) reported AET was sometimes discussed, and 16% (29/179) reported 
AET was never discussed.  41% (86/210) of the total sample reported having discussed AET 
with their GP.  No significant associations were found between response to ‘discussed at 
hospital appointments’ or ‘discussed with GP’ and non-adherence.   
 
Demographic factors and adherence 
Younger age (<65 years) (χ2= .0.283 (df 1), p=0.01), higher education (completed college 
education and above) (χ2= .0.140 (df 1), p=0.046), and  in paid employment (χ2= .0.174 (df 
1), p=0.031 were significantly associated with unintentional non-adherence.   
No significant associations between demographic factors and intentional non-adherence were 
found. 
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Multivariate analysis of factors predicting non-adherence 
Logistic regression was performed to identify predictors of non-adherence to AET.  The 
factors included were: BMQ Necessity (continuous total scores), BMQ Concerns (continuous 
total scores) BMQ Harm (continuous total scores) and BMQ Overuse (continuous total 
scores), side effects (yes/no), age (in years), education (post-secondary/secondary or less), 
and employment status (in paid employment/not in paid employment) (see Table 5).  
Only two variables were found to be significant predictors of non-adherence: side effects (OR 
4.383 CI 1.601-12.002, p<0.04) and BMQ Concerns (OR: 1.181 CI 1.033-1.350, p< 0.015). 
Eliminating non-significant factors from the model had little effect on the model. The sample 
size was not large enough to allow separate predictors of intentional and unintentional non-
adherence to be calculated 
 
Discussion: 
This study explored differences between non-adherers and adherers to AET in women with 
breast cancer, with regard to medication beliefs, side effects, and support provided, and 
reports factors associated with intentional and unintentional non-adherence.  The strongest 
predictors of non-adherence in the sample as a whole were the presence of side effects, and 
having significant concerns about taking AET.  Intentional non-adherence was significantly 
associated with concerns about taking AET, side effects, and lower belief in the necessity of 
taking AET.   Unintentional non-adherence was associated with younger age (<65), in paid 
employment, and a higher level of education. 
 
AETs are known to have a significant side effect profile which can adversely affect quality of 
life and have previously been cited as barriers to continuing with treatment (Harrow et al, 
2013; Morgan & Fenlon 2013; Fenlon et al, 2009; Cella & Fallowfield 2008).  In our study, 
nearly two thirds of women reported side effects they attributed to AET, with most reporting 
a moderate to high impact on their daily lives. The association between side effects and 
intentional non-adherence was calculated using the total number of women reporting any side 
effects. The relationship with intentional non-adherence was stronger for women whose side 
effects had a moderate or high impact on their lives.   With an increasing number of women 
surviving breast cancer, and increasing periods of time on AET now being recommended 
(Gray 2013), there is a pressing need for effective interventions to manage symptoms for this 
patient group.   Side effects can sometimes be managed by switching to another preparation 
or to another agent, if appropriate to women’s menopausal status.  Pharmacological treatment 
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may alleviate the symptoms of AET, including small doses of the selective serotonin reuptake 
inhibitor (SSRI) anti-depressants, such as venlafaxine and citalopram (Archer et al, 2009), 
anti-epileptic drugs (gabapentin) (Pandya et al, 2005, and progesterones (Bertelli et al, 2002).  
Some women may prefer use of complementary therapies, although there is limited evidence 
of their effectiveness (Chiu et al, 2015).  
 
The influence of concerns with taking AET on non-adherence have also been explored in 
other studies (Wouter et al, 2013; Grunfeld et al, 2005; Stanton et al, 2014).   Alongside the 
relatively well known side effects that women can experience, such concerns may include 
fear of long-term risks of taking AET, such as deep venous thrombosis, pulmonary embolism 
or endometrial cancer from tamoxifen and osteoporotic fracture from AIs.  Furthermore, 
women may be reluctant to take additional ‘toxic’ medication following surgery, 
chemotherapy and radiotherapy particularly if they lack confidence in the value of the 
medication. 
 
Factors associated with unintentional non-adherence have not previously been identified in 
this population. A review of the evidence exploring common factors causing therapeutic non-
compliance reported that younger working women are more likely to be poor adherers due to 
juggling work and family (Jin et al, 2008).  This may relate to women in this study too, 
although further investigation is needed. 
 
The results of this study also support studies that have explored non-adherence to a broad 
spectrum of medications.   A meta-synthesis of qualitative studies looking at adherence to 
medications in general reported that the main reason people do not adhere is because of 
concerns about the medicines themselves, such as worries of dependence, tolerance and 
addiction, the potential harm from taking medicines on a long-term basis and the possibility 
that medicine masks other symptoms (Pound et al, 2005).  Furthermore, a meta–analysis of 
studies which have used the necessity-concerns framework (Horne et al, 2013) found that 
higher adherence was associated with fewer concerns about treatment, and stronger 
perceptions of necessity of treatment.   
 
While results of this study supports previous qualitative studies that have explored themes 
relating to non-adherence to AET (Wouter et al, 2013, Harrow et al, 2013; Vergbrugghe et al, 
2015; Cahir et al, 2015; Flanagan et al, 2012; Pellefrini et al, 2010), the study adds to the 
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literature by dividing non-adherers into intentional and unintentional non-adherence 
categories, and by identifying the most significant factors associated with these categories.  
Strategies to improve adherence will have to recognise that implicit unconscious processes 
(such as unintentional non-adherence) and the more explicit conscious (intentional) processes 
exist (Strack & Deutsch 2004).  It may prove useful for health professionals to distinguish 
between those who are intentional non-adherers and those who are unintentional non-
adherers to tailor support and interventions. 
 
While fostering tailored interventions that address non-adherence to AET are needed, further 
research is also needed around who is best placed to deliver these interventions   Currently 
there is no formal monitoring of adherence or standardised protocol for discussing AET, 
either in hospital or community (Harrow et al 2013).   The trend towards shorter hospital 
follow-up further reduces the availability of hospital specialist advice and support for women, 
suggesting innovative models of community-based follow-up are required.  While ongoing 
prescriptions for AET are provided by the GP in the UK, only 41% of women in this study 
had discussed AET with their GP.  We know of no interventions designed to help the GP in 
supporting women taking AET, highlighting the need for research in this area.  More 
recently, the growing role of the community pharmacist has been recognised to alleviate 
pressure from GPs (NHS 2013). Positive relationships between women taking AET and 
community pharmacies could aid frequent monitoring, support and feedback, and aid changes 
in beliefs about the medication.  Pharmacy interventions such as electronic prescription 
service (EPS), online repeat prescriptions and reminders of repeat prescriptions, extended 
intervals between prescriptions, home delivery and blister packs may help improve adherence 
in the unintentional adherers (Claxton et al, 2001; Omran et al, 2012).   
 
In the UK, the Cancer Reform Strategy in 2007 and the All Party Parliamentary Group in 
their report on inequalities in cancer published in December 2009 recognised the importance 
of follow-up strategies for cancer survivors.  The Cancer strategy (2015) recommends more 
tailored care in this phase as this has the potential to reduce costs through reducing 
recurrences, better managing side-effects and supporting people to live well (Independent 
Cancer Force, 2015). Stratified follow-up pathways – which comprise holistic needs 
assessment, support for patients to self-manage, and remote monitoring could offer a more 
effective approach to aftercare for this group of women than traditional medical models of 
follow-up. There is evidence in breast and colorectal cancer that stratified follow-up 
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pathways deliver improved quality of care.  Outpatient follow-up appointments and the 
Cancer Care Review GPs are recommended to conduct at 6 months post diagnosis represent 
potential opportunities for assessing concerns about AET and the impact of side-effects as 
part of follow-up.   
 
Alongside these more practical interventions, novel ways in which health professionals could 
improve adherence through e-health interventions such as tailoring of messages through 
smart phones and tablets as a method of developing communication to influence specific 
health-related behaviours have been suggested (Dayer et al, 2013) [58].  The evidence to date 
suggests that these tailored health messages can improve medical adherence (Mosa et al, 
2012).   
 
Limitations of this study include those common to postal surveys, including the potential for 
non-response bias and accuracy of self-report.  Participants are a self-selected sample, who 
had previously taken part in the JACS study.  Furthermore, the sample size of non-adherers 
was too small to perform logistic regression separately for the intentional and unintentional 
non-adherers. However, the strengths include a good response rate providing a sufficient 
sample size to conduct a range of analyses. Association with co-morbidities was not 
calculated.  Eighty three percent of women reported having ‘other health conditions’, but the 
data presented a diverse range of ‘other health conditions’ and the severity of these co-
morbidities and whether medication was taken for these conditions was not reported.  Future 
studies should explore the impact of co-morbidities and polypharmacy on patients’ lives and 
the extent to which these groups adhere to AET. 
 
 
Conclusions: 
This study has highlighted factors that influence intentional and unintentional non-adherence 
in women taking AETs following treatment for breast cancer, and points to the need for 
interventions to support and monitor these women throughout their five to 10 years of AET. 
Future development of interventions to improve adherence to medication would benefit from 
paying particular attention to both intentional and unintentional aspects of non-adherence; 
interventions both to manage the side effect profile of AET and to modify particular 
medication-based beliefs seem especially relevant behaviour change strategies for this 
population. Novel approaches to improve adherence to AET through GP practices, 
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community pharmacists, or via e-health interventions may be useful.  As increasing numbers 
of women are diagnosed with breast cancer, it is essential we optimise the management of 
women prescribed AET and find strategies which help women persist with therapy in order to 
reduce recurrence of disease and mortality.   
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